Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Prevalence of medication transfer errors in nephrology patients and potential risk factors.

Ebbens MM, Errami H, Moes DJAR, van den Bemt PMLA, van der Boog PJM, Gombert-Handoko KB.

Eur J Intern Med. 2019 Oct 9. pii: S0953-6205(19)30316-4. doi: 10.1016/j.ejim.2019.09.003. [Epub ahead of print]

PMID:
31606307
2.

Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.

Groenland SL, van Eerden RAG, Verheijen RB, Koolen SLW, Moes DJAR, Desar IME, Reyners AKL, Gelderblom HJ, van Erp NP, Mathijssen RHJ, Huitema ADR, Steeghs N.

Ther Drug Monit. 2019 Oct;41(5):561-567. doi: 10.1097/FTD.0000000000000654.

PMID:
31568233
3.

Beyond Survival in Solid Organ Transplantation: A Summary of Expert Presentations from the Sandoz 6th Standalone Transplantation Meeting, 2018.

Legendre C, Viebahn R, Crespo M, Dor F, Gustafsson B, Samuel U, Karam V, Binet I, Aberg F, De Geest S, Moes DJAR, Tonshoff B, Oppenheimer F, Asberg A, Halleck F, Loupy A, Suesal C.

Transplantation. 2019 Sep;103(9S1 Suppl 1):S1-S13. doi: 10.1097/TP.0000000000002846. No abstract available.

PMID:
31449167
4.

A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors.

Yin A, Moes DJAR, van Hasselt JGC, Swen JJ, Guchelaar HJ.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun 28. doi: 10.1002/psp4.12450. [Epub ahead of print] Review.

5.

Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.

Loeff FC, van Egmond EHM, Moes DJAR, Wijnands C, Von Dem Borne PA, Veelken H, Falkenburg JHF, Jedema I, Halkes CJM.

Transpl Immunol. 2019 Jun 14:101209. doi: 10.1016/j.trim.2019.06.001. [Epub ahead of print]

6.

Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.

van der Stoep MYEC, Zwaveling J, Bertaina A, Locatelli F, Guchelaar HJ, Lankester AC, Moes DJAR.

Br J Clin Pharmacol. 2019 Sep;85(9):2033-2044. doi: 10.1111/bcp.13995. Epub 2019 Jul 1.

7.

The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).

Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.

Clin Pharmacol Ther. 2019 Nov;106(5):1076-1082. doi: 10.1002/cpt.1515. Epub 2019 Jul 9.

PMID:
31125423
8.

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.

Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S.

Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640.

PMID:
31045868
9.

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.

Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJAR, Gelderblom H, Guchelaar HJ.

Expert Rev Clin Pharmacol. 2019 Jun;12(6):523-536. doi: 10.1080/17512433.2019.1610390. Epub 2019 Apr 30. Review.

PMID:
31008668
10.

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.

Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC.

Clin Pharmacokinet. 2019 Jul;58(7):835-857. doi: 10.1007/s40262-019-00748-2. Review.

11.

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ.

Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8. Review.

12.

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.

Sanchez-Spitman A, Dezentjé V, Swen J, Moes DJAR, Böhringer S, Batman E, van Druten E, Smorenburg C, van Bochove A, Zeillemaker A, Jongen L, Los M, Neven P, Gelderblom H, Guchelaar HJ.

J Clin Oncol. 2019 Mar 10;37(8):636-646. doi: 10.1200/JCO.18.00307. Epub 2019 Jan 24.

PMID:
30676859
13.

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.

Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, Elens L, Moes DJAR, de Winter BCM.

Br J Clin Pharmacol. 2019 Mar;85(3):601-615. doi: 10.1111/bcp.13838. Epub 2019 Jan 17.

14.

Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.

Woei-A-Jin FJSH, Van Nieuwenhuyse T, van Erp NP, Beuselinck B, Stroobants S, Moes DJAR, Osanto S, Spriet I.

J Clin Oncol. 2018 Oct 20;36(30):3062-3064. doi: 10.1200/JCO.2018.79.3182. Epub 2018 Sep 6. No abstract available.

PMID:
30188790
15.

Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device.

Zwart TC, Gokoel SRM, van der Boog PJM, de Fijter JW, Kweekel DM, Swen JJ, Guchelaar HJ, Moes DJAR.

Br J Clin Pharmacol. 2018 Dec;84(12):2889-2902. doi: 10.1111/bcp.13755. Epub 2018 Oct 15.

PMID:
30176064
16.

Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.

Sanchez-Spitman AB, Dezentjé VO, Swen JJ, Moes DJAR, Gelderblom H, Guchelaar HJ.

Breast Cancer Res Treat. 2018 Nov;172(2):401-411. doi: 10.1007/s10549-018-4923-7. Epub 2018 Aug 17.

17.

A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.

Ter Heine R, van Erp NP, Guchelaar HJ, de Fijter JW, Reinders MEJ, van Herpen CM, Burger DM, Moes DJAR.

Br J Clin Pharmacol. 2018 Jul;84(7):1575-1586. doi: 10.1111/bcp.13591. Epub 2018 May 6.

18.

Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).

Boerlage TCC, Haal S, Maurits de Brauw L, Acherman YIZ, Bruin S, van de Laar AWJM, Moes DE, van Wagensveld BA, de Vries CEE, van Veen R, Schouten R, Dijkgraaf MG, Fockens P, Gerdes VEA, Voermans RP.

BMC Gastroenterol. 2017 Dec 20;17(1):164. doi: 10.1186/s12876-017-0674-x.

19.

High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.

van der Stoep MYEC, Bertaina A, Ten Brink MH, Bredius RG, Smiers FJ, Wanders DCM, Moes DJAR, Locatelli F, Guchelaar HJ, Zwaveling J, Lankester AC.

Br J Haematol. 2017 Dec;179(5):772-780. doi: 10.1111/bjh.14960. Epub 2017 Oct 19.

PMID:
29048102
20.

Can a laparoscopic Roux-en-Y gastric bypass be safely performed by surgical residents in a bariatric center-of-excellence? The learning curve of surgical residents in bariatric surgery.

van Rijswijk AS, Moes DE, Geubbels N, Hutten BA, Acherman YIZ, van de Laar AW, de Brauw M, Bruin SC.

Surg Endosc. 2018 Feb;32(2):1012-1020. doi: 10.1007/s00464-017-5779-3. Epub 2017 Sep 21.

PMID:
28936562
21.

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ.

Eur J Clin Pharmacol. 2017 Dec;73(12):1589-1598. doi: 10.1007/s00228-017-2323-2. Epub 2017 Aug 28.

22.

The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.

Sanchez-Spitman AB, Moes DA, Gelderblom H, Dezentjé VO, Swen JJ, Guchelaar HJ.

Pharmacogenomics. 2017 Aug;18(12):1125-1132. doi: 10.2217/pgs-2017-0080. Epub 2017 Jul 26.

PMID:
28745555
23.

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.

Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U.

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13.

24.

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients.

Bank JR, Heidt S, Moes DJ, Roelen DL, Mallat MJ, van der Boog PJ, Vergunst M, Jol-van der Zijde CM, Bredius RG, Braat AE, Ringers J, van Tol MJ, Claas FH, Reinders ME, de Fijter JW.

Transplant Direct. 2016 Dec 19;3(1):e124. doi: 10.1097/TXD.0000000000000634. eCollection 2017 Jan.

25.

Population pharmacokinetics of lenalidomide in multiple myeloma patients.

Guglieri-López B, Pérez-Pitarch A, Moes DJ, Porta-Oltra B, Climente-Martí M, Guchelaar HJ, Merino-Sanjuán M.

Cancer Chemother Pharmacol. 2017 Jan;79(1):189-200. doi: 10.1007/s00280-016-3228-y. Epub 2016 Dec 30.

PMID:
28039509
26.

Aorto-oesophageal fistula after oesophageal stent placement in a patient with a Roux-en-Y gastric bypass.

Boerlage TC, Hermanides HS, Moes DE, Tan IL, Houben GM, Acherman YI.

Ann R Coll Surg Engl. 2016 Nov;98(8):e178-e180. Epub 2016 Aug 11.

27.

Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial.

Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters-Sengers H, de Maar EF, van der Pant KA, de Vries AP, Sanders JS, Zwinderman A, Idu MM, Berger S, Reinders ME, Krikke C, Bajema IM, van Dijk MC, Ten Berge IJ, Ringers J, Lardy J, Roelen D, Moes DJ, Florquin S, Homan van der Heide JJ.

Am J Transplant. 2017 Apr;17(4):1020-1030. doi: 10.1111/ajt.14048. Epub 2016 Oct 17.

28.

Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.

Moes DJ, Press RR, Ackaert O, Ploeger BA, Bemelman FJ, Diack C, Wessels JA, van der Straaten T, Danhof M, Sanders JS, Homan van der Heide JJ, Guchelaar HJ, de Fijter JW.

Br J Clin Pharmacol. 2016 Jul;82(1):227-37. doi: 10.1111/bcp.12946. Epub 2016 May 10.

29.

Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.

de Wit D, Schneider TC, Moes DJ, Roozen CF, den Hartigh J, Gelderblom H, Guchelaar HJ, van der Hoeven JJ, Links TP, Kapiteijn E, van Erp NP.

Cancer Chemother Pharmacol. 2016 Jul;78(1):63-71. doi: 10.1007/s00280-016-3050-6. Epub 2016 May 11.

30.

Response: Limited sampling strategies for once daily tacrolimus exposure monitoring.

Moes DJ, Swen JJ, van der Bent SA, van der Straaten T, Inderson A, Olofsen E, Verspaget HW, Guchelaar HJ, den Hartigh J, van Hoek B.

Eur J Clin Pharmacol. 2016 Jun;72(6):775-6. doi: 10.1007/s00228-016-2036-y. Epub 2016 Mar 2. No abstract available.

PMID:
26931555
31.

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.

Moes DJ, van der Bent SA, Swen JJ, van der Straaten T, Inderson A, Olofsen E, Verspaget HW, Guchelaar HJ, den Hartigh J, van Hoek B.

Eur J Clin Pharmacol. 2016 Feb;72(2):163-74. doi: 10.1007/s00228-015-1963-3. Epub 2015 Oct 31.

32.

The pH sensibility of actin-bundling LIM proteins is governed by the acidic properties of their C-terminal domain.

Moes D, Hoffmann C, Dieterle M, Moreau F, Neumann K, Papuga J, Furtado AT, Steinmetz A, Thomas C.

FEBS Lett. 2015 Aug 19;589(18):2312-9. doi: 10.1016/j.febslet.2015.07.033. Epub 2015 Jul 29.

33.

Sirolimus and everolimus in kidney transplantation.

Moes DJ, Guchelaar HJ, de Fijter JW.

Drug Discov Today. 2015 Oct;20(10):1243-9. doi: 10.1016/j.drudis.2015.05.006. Epub 2015 Jun 4. Review.

PMID:
26050578
34.

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.

Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, Bemelman FJ, de Fijter JW, Guchelaar HJ.

CPT Pharmacometrics Syst Pharmacol. 2014 Feb 12;3:e100. doi: 10.1038/psp.2013.78.

35.

Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients.

Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, van der Heide JJ, van Dijk M, ten Berge IJ, Bemelman FJ.

Transpl Int. 2014 May;27(5):428-36. doi: 10.1111/tri.12275. Epub 2014 Mar 5.

36.

Live cell imaging reveals actin-cytoskeleton-induced self-association of the actin-bundling protein WLIM1.

Hoffmann C, Moes D, Dieterle M, Neumann K, Moreau F, Tavares Furtado A, Dumas D, Steinmetz A, Thomas C.

J Cell Sci. 2014 Feb 1;127(Pt 3):583-98. doi: 10.1242/jcs.134536. Epub 2013 Nov 27. Erratum in: J Cell Sci. 2014 Mar 15;127(Pt 6):1357.

37.

Free Intra-Abdominal Air without Peritoneal Perforation after TEM: A Report of Two Cases.

Franken RJ, Moes DE, Acherman YI, Derksen EJ.

Case Rep Surg. 2012;2012:185429. doi: 10.1155/2012/185429. Epub 2012 Dec 17.

38.

A LIM domain protein from tobacco involved in actin-bundling and histone gene transcription.

Moes D, Gatti S, Hoffmann C, Dieterle M, Moreau F, Neumann K, Schumacher M, Diederich M, Grill E, Shen WH, Steinmetz A, Thomas C.

Mol Plant. 2013 Mar;6(2):483-502. doi: 10.1093/mp/sss075. Epub 2012 Aug 28.

39.

Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.

Moes DJ, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ.

Clin Pharmacokinet. 2012 Jul 1;51(7):467-80. doi: 10.2165/11599710-000000000-00000.

PMID:
22624503
40.

Bioinformatics as a driver, not a passenger, of translational biomedical research: Perspectives from the 6th Benelux bioinformatics conference.

Azuaje FJ, Heymann M, Ternes AM, Wienecke-Baldacchino A, Struck D, Moes D, Schneider R.

J Clin Bioinforma. 2012 Mar 13;2:7. doi: 10.1186/2043-9113-2-7.

41.

Arabidopsis actin-depolymerizing factors (ADFs) 1 and 9 display antagonist activities.

Tholl S, Moreau F, Hoffmann C, Arumugam K, Dieterle M, Moes D, Neumann K, Steinmetz A, Thomas C.

FEBS Lett. 2011 Jun 23;585(12):1821-7. doi: 10.1016/j.febslet.2011.05.019. Epub 2011 May 11.

42.

Arabidopsis LIM proteins: a family of actin bundlers with distinct expression patterns and modes of regulation.

Papuga J, Hoffmann C, Dieterle M, Moes D, Moreau F, Tholl S, Steinmetz A, Thomas C.

Plant Cell. 2010 Sep;22(9):3034-52. doi: 10.1105/tpc.110.075960. Epub 2010 Sep 3.

43.

Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation.

Moes DJ, Press RR, de Fijter JW, Guchelaar HJ, den Hartigh J.

Ther Drug Monit. 2010 Aug;32(4):413-9. doi: 10.1097/FTD.0b013e3181e5c656.

PMID:
20535052
44.

Actin bundling in plants.

Thomas C, Tholl S, Moes D, Dieterle M, Papuga J, Moreau F, Steinmetz A.

Cell Motil Cytoskeleton. 2009 Nov;66(11):940-57. doi: 10.1002/cm.20389. Review.

PMID:
19504571
45.

Regulators of PP2C phosphatase activity function as abscisic acid sensors.

Ma Y, Szostkiewicz I, Korte A, Moes D, Yang Y, Christmann A, Grill E.

Science. 2009 May 22;324(5930):1064-8. doi: 10.1126/science.1172408. Epub 2009 Apr 30.

46.

Nuclear localization of the mutant protein phosphatase abi1 is required for insensitivity towards ABA responses in Arabidopsis.

Moes D, Himmelbach A, Korte A, Haberer G, Grill E.

Plant J. 2008 Jun;54(5):806-19. doi: 10.1111/j.1365-313X.2008.03454.x. Epub 2008 Feb 22.

47.

Integration of abscisic acid signalling into plant responses.

Christmann A, Moes D, Himmelbach A, Yang Y, Tang Y, Grill E.

Plant Biol (Stuttg). 2006 May;8(3):314-25. Review.

PMID:
16807823
48.

Giving birth: a midwife's faith in birth is reborn.

Moes D.

Midwifery Today Int Midwife. 2005 Winter;(76):30-1. No abstract available.

PMID:
16419668
49.
50.

Supplemental Content

Support Center